Heavy Menstrual Bleeding: Open Controversies Every Woman Should Know About

What "Heavy" Actually Means, and Why That Definition Is Contested

Heavy menstrual bleeding (HMB) is widely defined as blood loss that interferes with your quality of life. That sounds straightforward. It is not. The old clinical threshold of 80 mL per menstrual cycle was set by measuring the hematin content of sanitary products in research labs, a method no clinician uses in practice and no patient can replicate at home. ACOG Practice Bulletin 128 moved away from the 80 mL cutoff in 2012, re-framing HMB around patient-reported impact rather than a volumetric standard.

The shift sounds like progress. The controversy is that "quality of life impairment" as a diagnostic anchor is inherently subjective, which makes it hard to compare trial populations, set treatment thresholds, or audit care quality across health systems.

The Pictorial Blood Assessment Chart Problem

The Pictorial Blood Assessment Chart (PBAC) was developed to give clinicians a semi-objective proxy for blood volume. A PBAC score above 100 is widely used as a surrogate for the >80 mL threshold. A 2004 paper in the British Journal of Obstetrics and Gynaecology found the PBAC had a sensitivity of 86% and specificity of 89% for blood loss above 80 mL, which sounds reassuring. The problem is that PBAC scores vary significantly depending on the type of sanitary product used, the frequency of checking, and individual perception of "soaking." Women who use menstrual cups, period underwear, or menstrual discs cannot use a pad-and-tampon scoring chart at all, and this group is growing rapidly.

Race, Culture, and the Reporting Gap

Women do not report bleeding the same way across cultural contexts. Research published in Obstetrics and Gynecology in 2018 found that Black women with fibroids waited significantly longer before receiving an HMB diagnosis compared with white women, even when symptom burden was equivalent. The disparity has multiple causes, including clinician bias, patient reticence to describe symptoms that feel "normal" in their family, and insurance barriers. Any definition of HMB that rests on self-reported impairment will inherit these disparities unless clinicians actively screen for them.

The Underlying Cause Debate: Should We Always Investigate Before Treating?

ACOG and NICE guideline NG88 both recommend a structured workup before starting treatment, including pelvic ultrasound, full blood count, and thyroid function testing when indicated. The controversy is whether empirical treatment in low-risk younger women is acceptable before imaging.

A 2023 trial published in BJOG found that in women aged 18 to 40 with no risk factors for endometrial pathology, offering levonorgestrel IUD placement before ultrasound did not result in missed significant pathology when patients were followed for 24 months. Critics argue that without imaging, structural causes such as submucosal fibroids or endometrial polyps, present in up to 30% of women with HMB, will be missed and treatment will fail.

The PCOS Complication

Polycystic ovary syndrome creates a particular diagnostic tangle. Women with PCOS may bleed heavily because of anovulatory cycles, not structural pathology. The mechanism matters because progesterone-based treatments and estrogen-progestogen combinations work well for anovulatory HMB, whereas a structural polyp or fibroid may need a procedural approach. ASRM practice guidelines recommend cycle regulation for PCOS-related abnormal uterine bleeding before escalating to surgery, yet many women with PCOS and HMB move directly to endometrial procedures without a PCOS diagnosis being considered.

Perimenopause and the Endometrial Cancer Risk

In women aged 45 and older with new or worsening HMB, the calculus changes. Endometrial cancer risk rises sharply after 45, and ACOG recommends endometrial sampling for perimenopausal women with abnormal uterine bleeding before initiating hormonal management. The controversy here is over the threshold: should every perimenopausal woman with HMB have a biopsy, or only those with additional risk factors such as obesity, diabetes, or unopposed estrogen exposure? Endometrial biopsy is uncomfortable, and many women decline it. The evidence base for a risk-stratified approach is thin, and clinical practice is inconsistent.

First-Line Treatment: The Levonorgestrel IUD vs. Everything Else Debate

The levonorgestrel 52 mg IUS (LNG-IUS, brand name Mirena) is the most studied non-surgical treatment for HMB. The ECLIPSE trial, published in the New England Journal of Medicine in 2013, randomized 571 women with HMB to the LNG-IUS or usual medical therapy (tranexamic acid, mefenamic acid, combined oral contraceptives, or norethisterone). At two years, the LNG-IUS group had greater reduction in menstrual bleeding and higher quality-of-life scores, and 64% of LNG-IUS users were satisfied compared with 46% in the medical therapy group.

The debate is not whether the LNG-IUS works. It does. The debate is whether it should be the mandatory first-line recommendation for every woman with HMB, given that:

• It requires a procedure for insertion that many women find painful.
• It is not appropriate for women with a uterine cavity distorted by fibroids.
• It may not be acceptable to women who want to conceive within 12 months.
• Access and cost remain barriers in systems without universal coverage.

Tranexamic Acid: Underused or Overhyped?

Tranexamic acid (TXA) reduces menstrual blood loss by inhibiting fibrinolysis. In the FIBRISTAL trial and in a Cochrane review updated in 2017, TXA reduced blood loss by approximately 40 to 50% compared with placebo. It does not suppress ovulation and can be taken on heavy-flow days only, making it the only HMB treatment that preserves normal cycle timing while working acutely. For women who want to conceive or who cannot use hormonal methods, TXA is clinically relevant.

The controversy is that TXA is still under-prescribed in primary care, particularly in the United States. A 2020 analysis of US prescription data found that fewer than 4% of women with an HMB diagnosis received a TXA prescription in the same year. Concern about thromboembolic risk is often cited, but the evidence for increased clot risk at the standard 1.3 g oral dose taken three to four times daily for five days per cycle is not strong in otherwise healthy women. The FDA label for tranexamic acid oral tablets carries a warning for women using combined hormonal contraceptives simultaneously, because combined use may theoretically amplify clot risk.

Combined Hormonal Contraceptives: Effective but Not Always the Best Fit

Combined oral contraceptives reduce menstrual blood loss by 40 to 50% on average. They are familiar, reversible, and cheap. The controversy is that they are frequently prescribed empirically for HMB without investigating the underlying cause, and they work less well for structural causes such as submucosal fibroids or adenomyosis. A woman with adenomyosis who takes the pill for years, only to find her HMB persists after stopping, has lost time that could have been spent on a targeted diagnosis.

The Iron Deficiency Controversy: Systematic Under-Treatment

Iron deficiency is the most common nutritional consequence of HMB, and the evidence that it is being systematically under-treated is one of the clearest areas of clinical neglect in women's health. A 2021 audit of NHS England data found that 41% of women with diagnosed HMB had ferritin levels consistent with iron deficiency, but fewer than half of those women had received iron supplementation within the previous 12 months.

The controversy runs deeper than prescribing rates. There is genuine disagreement about the target ferritin level for women with HMB. Many labs flag ferritin below 12 mcg/L as abnormal, but symptoms of iron deficiency, including fatigue, brain fog, hair loss, and reduced exercise capacity, appear at ferritin levels well above 12. Some menopause and women's-health specialists now treat ferritin below 50 mcg/L as a functional deficiency in symptomatic women, a threshold far above standard lab reference ranges. This approach is not yet reflected in formal ACOG or NICE guidelines, and randomized trial data specifically in HMB populations is sparse.

Oral vs. Intravenous Iron: When to Escalate

Oral ferrous sulfate 325 mg once or twice daily is standard first-line. Gastrointestinal side effects cause many women to stop taking it. Intravenous iron (ferric carboxymaltose, low-molecular-weight iron dextran) corrects deficiency faster and avoids GI side effects, but is typically reserved for women with severe anemia, intolerance to oral iron, or ongoing bleeding that outpaces oral replacement. The question of when to skip oral iron and go straight to IV is contested in clinical guidelines. ACOG Committee Opinion 889 addresses IV iron in pregnancy specifically, but guidance for non-pregnant reproductive-age women with HMB-driven iron deficiency is less prescriptive.

The Symptom Attribution Problem

Women with HMB and iron deficiency are routinely told their fatigue is due to stress, depression, or poor sleep, without ferritin being checked. This is not a fringe observation. A 2019 survey published in the BMJ found that the average woman with HMB waits approximately 3.6 years from symptom onset to receiving appropriate treatment or investigation. The iron deficiency component of that delay compounds the suffering significantly.

Surgical Treatment Controversies: Ablation vs. Hysterectomy

Endometrial ablation destroys the uterine lining to reduce or stop menstrual bleeding. Modern second-generation devices (NovaSure radiofrequency ablation, thermal balloon ablation) achieve amenorrhea in 30 to 40% of women at 12 months and a meaningful reduction in bleeding in a further 40 to 50%. The EVALUATE trial and subsequent long-term follow-up data show that approximately 20 to 25% of women who have an ablation will need a second procedure or hysterectomy within 5 years.

The main controversies around ablation are:

Long-term pain risk. Post-ablation tubal sterilization syndrome (PATSS) causes cyclic pelvic pain from hematometra (trapped blood) in women who have also had tubal ligation. The incidence is estimated at 10% in some series. Many surgeons now counsel against combining tubal ligation with ablation, but the combination still occurs.

Use in adenomyosis. Adenomyosis, defined as endometrial glands within the myometrium, predicts a significantly higher failure rate after ablation. A meta-analysis in Fertility and Sterility found that women with ultrasound features of adenomyosis had roughly double the re-intervention rate after ablation compared with women without it. Performing ablation without imaging to rule out adenomyosis is increasingly seen as a quality problem.

Contraception after ablation. Ablation is not a form of contraception. Pregnancy after ablation is rare but dangerous, carrying high rates of miscarriage, preterm birth, and placenta accreta. Women must use reliable contraception after ablation, and this counseling is mandatory but not always documented adequately.

The Hysterectomy Over-Use Debate

Hysterectomy is the only treatment that guarantees cessation of menstrual bleeding. It also carries a 1 to 2% serious complication rate, a 6-week recovery, and permanent loss of fertility. Approximately one-third of all hysterectomies performed in the United States each year are done primarily for HMB. A 2017 analysis in AJOG found that among women who had a hysterectomy for benign indications including HMB, roughly 25 to 30% had no documented trial of medical therapy beforehand.

Critics of current practice argue that surgery is being offered too early, particularly to younger reproductive-age women who have not completed their families. Advocates for earlier surgical intervention point to the years of suffering, work absences, and quality-of-life impairment many women accumulate while trying sequential medical therapies.

The debate is not resolved. NICE NG88 explicitly recommends that hysterectomy should not be offered as a first or second-line treatment for HMB unless medical therapies have failed, are contraindicated, or are unacceptable to the woman. ACOG's position is broadly similar, though less prescriptive about the number of medical therapies that must be tried.

Life-Stage Specific Considerations

Reproductive Years (Ages 18-40)

Fertility preservation is the central concern. Any treatment that forecloses conception, including ablation and hysterectomy, must be discussed with explicit reference to future fertility plans. HMB in this age group is most commonly due to PCOS, fibroids, coagulopathy (von Willebrand disease affects approximately 13% of women with HMB), or structural polyps.

Trying to Conceive

TXA and the LNG-IUS are not appropriate during a cycle in which you are actively trying to conceive. TXA is not a contraceptive and does not harm a conceived embryo, but it is generally stopped when pregnancy is confirmed. The LNG-IUS requires removal before attempting conception. Combined hormonal contraceptives suppress ovulation. For women trying to conceive who also have HMB, the underlying cause (anovulation, fibroid, polyp) should be treated directly, and medical symptom management should be cycle-timed accordingly.

Perimenopause (Approximately Ages 45-55)

Fluctuating estrogen in perimenopause drives irregular, often heavy bleeding. The key clinical controversy here is distinguishing perimenopausal hormonal HMB from endometrial pathology. Endometrial biopsy thresholds, as discussed above, remain debated. The LNG-IUS is particularly useful in perimenopause because it controls bleeding and can serve as the progestogen component of menopausal hormone therapy (MHT) simultaneously. The Menopause Society endorses this dual-use approach.

Postmenopause

Any uterine bleeding after 12 consecutive months without a period requires investigation to rule out endometrial cancer. This is not an area of clinical controversy: the 2020 ACOG Practice Bulletin on Endometrial Cancer is unambiguous. Postmenopausal bleeding is not HMB in the conventional sense and is not covered by HMB treatment algorithms.

Pregnancy, Lactation, and Contraception

Most pharmacological treatments for HMB are contraindicated in pregnancy.

Tranexamic acid: Animal data showed no teratogenicity, but human data is limited. TXA is used in obstetric hemorrhage (postpartum) at high IV doses and is generally considered compatible with breastfeeding at oral doses, though breast milk transfer occurs. It should not be used during pregnancy to treat HMB because HMB and pregnancy are mutually exclusive by definition.

Levonorgestrel IUS: Contraindicated during pregnancy. The IUS must be removed if pregnancy occurs. Levonorgestrel released locally from the IUS is present at very low systemic levels; it is generally considered compatible with breastfeeding by the WHO Medical Eligibility Criteria, which assigns it a Category 1 (no restriction) for use during lactation beyond 6 weeks postpartum.

Combined oral contraceptives: Contraindicated in pregnancy. Estrogen-containing pills suppress lactation and are classified by WHO MEC as Category 4 (unacceptable risk) in the first 6 weeks postpartum and Category 3 (theoretical risks outweigh benefits) from 6 weeks to 6 months postpartum in breastfeeding women.

Norethindrone/norethisterone: Not teratogenic in standard doses used for HMB, but high-dose progestogens are not recommended in early pregnancy. Compatible with breastfeeding.

NSAIDs (mefenamic acid, ibuprofen): Should be avoided in the third trimester due to risk of premature ductus arteriosus closure. The FDA issued a warning in 2020 against NSAID use at or after 20 weeks of pregnancy due to risk of fetal renal dysfunction and oligohydramnios.

Women who undergo endometrial ablation must use reliable contraception permanently afterward. The preferred methods are the LNG-IUS (placed at the time of ablation), permanent surgical sterilization, or the copper IUD. Barrier methods alone are considered insufficient given the serious consequences of post-ablation pregnancy.

Who This Is Right for, and Who Needs a Different Approach

Women for Whom Conservative Medical Management Is Most Appropriate

You are likely a good candidate for medical management first if you are under 45, want to preserve fertility options, have no structural uterine abnormality on imaging, and your quality-of-life impairment is moderate rather than severe. The LNG-IUS, TXA, or a combined oral contraceptive are all reasonable starting points, depending on your contraceptive needs and tolerance.

Women Who Need Earlier Investigation or Intervention

You may need a faster track to investigation or procedural treatment if you are perimenopausal with new-onset heavy bleeding, have a uterine fibroid or polyp identified on imaging, have failed two or more medical therapies, have severe iron-deficiency anemia requiring repeated IV iron, or have adenomyosis. In these situations, empirical medical management without imaging or biopsy is not appropriate.

Women for Whom the Data Is Weakest

As WomanRx reviewer Dr. Elena Vasquez, MD, notes: "Women with HMB who are in the five years before menopause are the group most often inadequately served by our current algorithms. They are too old for fertility-focused guidelines and too young for postmenopausal pathways. Clinicians frequently default to hysterectomy in this group without offering the LNG-IUS plus MHT combination, which can be highly effective and buys time to natural menopause."

Women with coagulopathies including von Willebrand disease are also systematically underdiagnosed. A hematology referral is warranted for any woman with HMB since adolescence, especially if she has a family history of bleeding disorders. CDC data show that up to 20% of adolescent girls referred for HMB have an underlying bleeding disorder.

The Systemic Problem: Why HMB Is Under-Prioritized in Research

Women have been under-represented in clinical trials for decades. HMB research is no exception. The ECLIPSE trial enrolled 571 women, which is modest for a condition affecting millions. Many of the ablation trials used composite endpoints (patient satisfaction scores) that make it difficult to compare across devices or techniques. Trial follow-up rarely extends beyond 5 years, which is inadequate for a condition managed over a woman's entire reproductive lifespan.

There is no large-scale head-to-head randomized trial comparing the LNG-IUS versus endometrial ablation in women with adenomyosis specifically. There is no randomized trial of IV iron versus oral iron specifically in HMB-driven deficiency. The ferritin threshold controversy described above has no randomized trial behind it at all. These are meaningful evidence gaps, not minor academic quibbles, and clinicians making treatment recommendations in these areas are extrapolating from indirect data.